FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317952747> ?p ?o ?g. }

• W4317952747 abstract "Abstract Atopic dermatitis (AD) is a debilitating chronic inflammatory skin disease with fluctuating disease severity that requires long-term control. Patients report that complete or almost complete skin clearance is highly important as a treatment goal. Upadacitinib is a selective oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 vs. JAK2, JAK3, and tyrosine kinase 2. In this post-hoc analysis of the upadacitinib phase 3/3b studies, we analysed the time patients spent in skin clearance response states over 16 weeks with upadacitinib 15 mg (UPA 15) and 30 mg (UPA 30) compared to placebo and dupilumab. Data were from phase 3/3b multicenter, randomized, double-blinded studies comparing the safety and efficacy of upadacitinib to either placebo (Measure Up 1 and Measure Up 2) or dupilumab (Heads Up) in patients with moderate-to-severe AD. In the Measure Up 1 and Measure Up 2 studies, adults and adolescents were randomized to receive UPA 15, UPA 30 or a placebo once daily for 16 weeks. In the Heads Up study, adults were randomized to receive UPA 30 once daily or dupilumab 300 mg every 2 weeks beginning at week 2 following an initial loading dose of 600 mg. The days patients spent in skin clearance response states based on Eczema Area Severity Index (EASI) improvements ≥75%/90%/100% (EASI 75/90/100) from baseline were assessed. Missing data at study visits were imputed using non-responder imputation. Response states between study visits were interpolated using the last observation carried forward. Integrated data from Measure Up 1 and Measure Up 2 included 1683 adults and adolescents randomized to UPA 15 (N = 557), UPA 30 (N = 567), or placebo (N = 559); 44.0% were female, and 48.8% had previously received systemic therapy. In the Heads Up study, 692 adults were randomized to UPA 30 (N = 348) or dupilumab (N = 344); 45.5% were female, and 51.0% had previously received systemic therapy. Patients in Measure Up 1 and 2 taking UPA 15 or UPA 30 cumulatively spent a greater proportion of days in EASI 75 (UPA 15: 54.2%, UPA 30: 64.6%, Placebo: 10.2%), EASI 90 (UPA 15: 32.0%, UPA 30: 44.0%, Placebo: 3.2%), and EASI 100 (UPA 15: 7.5%, UPA 30: 13.5%, Placebo: 0.6%) response states compared to placebo over 16 weeks. In the Heads Up study, patients taking UPA 30 vs. dupilumab cumulatively spent a greater proportion of days in EASI 75 (58.9% vs. 36.9%), EASI 90 (42.1% vs. 19.1%), and EASI 100 (11.8% vs. 3.3%) response states over 16 weeks. Treatment of moderate-to-severe AD with UPA 15 or UPA 30 resulted in a greater proportion of days spent with higher levels of skin clearance (EASI 75/90/100) compared to placebo over 16 weeks, mirroring findings from the Heads Up study comparing UPA 30 to dupilumab. Increases in time spent with high levels of skin clearance with upadacitinib treatment may reflect improved long-term disease control and translate into more time spent experiencing a better quality of life that is less burdened by AD." @default.
• W4317952747 created "2023-01-25" @default.
• W4317952747 creator A5010968292 @default.
• W4317952747 creator A5011739266 @default.
• W4317952747 creator A5032393407 @default.
• W4317952747 creator A5070052210 @default.
• W4317952747 creator A5079812104 @default.
• W4317952747 creator A5080237247 @default.
• W4317952747 date "2023-01-25" @default.
• W4317952747 modified "2023-10-17" @default.
• W4317952747 title "355 Efficacy of upadacitinib for moderate-to-severe atopic dermatitis: analysis of time spent in skin clearance response states from the Measure Up 1, Measure Up 2 and Heads Up studies" @default.
• W4317952747 doi "https://doi.org/10.1093/bjd/ljac140.047" @default.
• W4317952747 hasPublicationYear "2023" @default.
• W4317952747 type Work @default.
• W4317952747 citedByCount "2" @default.
• W4317952747 countsByYear W43179527472023 @default.
• W4317952747 crossrefType "journal-article" @default.
• W4317952747 hasAuthorship W4317952747A5010968292 @default.
• W4317952747 hasAuthorship W4317952747A5011739266 @default.
• W4317952747 hasAuthorship W4317952747A5032393407 @default.
• W4317952747 hasAuthorship W4317952747A5070052210 @default.
• W4317952747 hasAuthorship W4317952747A5079812104 @default.
• W4317952747 hasAuthorship W4317952747A5080237247 @default.
• W4317952747 hasConcept C126322002 @default.
• W4317952747 hasConcept C142724271 @default.
• W4317952747 hasConcept C16005928 @default.
• W4317952747 hasConcept C168563851 @default.
• W4317952747 hasConcept C204787440 @default.
• W4317952747 hasConcept C27081682 @default.
• W4317952747 hasConcept C2776173921 @default.
• W4317952747 hasConcept C2778329239 @default.
• W4317952747 hasConcept C2779134260 @default.
• W4317952747 hasConcept C2780699399 @default.
• W4317952747 hasConcept C67761136 @default.
• W4317952747 hasConcept C71924100 @default.
• W4317952747 hasConcept C90924648 @default.
• W4317952747 hasConceptScore W4317952747C126322002 @default.
• W4317952747 hasConceptScore W4317952747C142724271 @default.
• W4317952747 hasConceptScore W4317952747C16005928 @default.
• W4317952747 hasConceptScore W4317952747C168563851 @default.
• W4317952747 hasConceptScore W4317952747C204787440 @default.
• W4317952747 hasConceptScore W4317952747C27081682 @default.
• W4317952747 hasConceptScore W4317952747C2776173921 @default.
• W4317952747 hasConceptScore W4317952747C2778329239 @default.
• W4317952747 hasConceptScore W4317952747C2779134260 @default.
• W4317952747 hasConceptScore W4317952747C2780699399 @default.
• W4317952747 hasConceptScore W4317952747C67761136 @default.
• W4317952747 hasConceptScore W4317952747C71924100 @default.
• W4317952747 hasConceptScore W4317952747C90924648 @default.
• W4317952747 hasIssue "Supplement_2" @default.
• W4317952747 hasLocation W43179527471 @default.
• W4317952747 hasOpenAccess W4317952747 @default.
• W4317952747 hasPrimaryLocation W43179527471 @default.
• W4317952747 hasRelatedWork W2003620798 @default.
• W4317952747 hasRelatedWork W2766528424 @default.
• W4317952747 hasRelatedWork W2916274906 @default.
• W4317952747 hasRelatedWork W2949235845 @default.
• W4317952747 hasRelatedWork W3195840880 @default.
• W4317952747 hasRelatedWork W3204561650 @default.
• W4317952747 hasRelatedWork W4237621822 @default.
• W4317952747 hasRelatedWork W4295338524 @default.
• W4317952747 hasRelatedWork W4320485560 @default.
• W4317952747 hasRelatedWork W4367553261 @default.
• W4317952747 hasVolume "188" @default.
• W4317952747 isParatext "false" @default.
• W4317952747 isRetracted "false" @default.
• W4317952747 workType "article" @default.